RXST

SEC source: 0000899243-21-031829 · doc4.xml · derivative · entry 7

Robertson Bruce C · CIK 0001289625 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 0

Underlying: Common Stock · 13,628 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Shares and warrant held by H.I.G. BioVentures - Calhoun, LLC. Affiliates of H.I.G. Capital manage all aspects of H.I.G. BioVentures - Calhoun, LLC. Anthony Tamer and Sami Mnaymneh are the managing partners of H.I.G. Capital and as such have the right to direct all activities related thereto. Alex Zisson, Dr. Michael Wasserman, and the Reporting Person are the managing directors of H.I.G. BioVentures - Calhoun, LLC, an affiliate of H.I.G. Capital. The Reporting Person disclaims beneficial ownership of the shares owned by H.I.G. BioVentures - Calhoun, LLC except to the extent of his pecuniary interests therein.

F2 · price: Shares and warrant held by H.I.G. BioVentures - Calhoun, LLC. Affiliates of H.I.G. Capital manage all aspects of H.I.G. BioVentures - Calhoun, LLC. Anthony Tamer and Sami Mnaymneh are the managing partners of H.I.G. Capital and as such have the right to direct all activities related thereto. Alex Zisson, Dr. Michael Wasserman, and the Reporting Person are the managing directors of H.I.G. BioVentures - Calhoun, LLC, an affiliate of H.I.G. Capital. The Reporting Person disclaims beneficial ownership of the shares owned by H.I.G. BioVentures - Calhoun, LLC except to the extent of his pecuniary interests therein.

F2 · derivative.exercise_date: Shares and warrant held by H.I.G. BioVentures - Calhoun, LLC. Affiliates of H.I.G. Capital manage all aspects of H.I.G. BioVentures - Calhoun, LLC. Anthony Tamer and Sami Mnaymneh are the managing partners of H.I.G. Capital and as such have the right to direct all activities related thereto. Alex Zisson, Dr. Michael Wasserman, and the Reporting Person are the managing directors of H.I.G. BioVentures - Calhoun, LLC, an affiliate of H.I.G. Capital. The Reporting Person disclaims beneficial ownership of the shares owned by H.I.G. BioVentures - Calhoun, LLC except to the extent of his pecuniary interests therein.

F2 · derivative.expiration_date: Shares and warrant held by H.I.G. BioVentures - Calhoun, LLC. Affiliates of H.I.G. Capital manage all aspects of H.I.G. BioVentures - Calhoun, LLC. Anthony Tamer and Sami Mnaymneh are the managing partners of H.I.G. Capital and as such have the right to direct all activities related thereto. Alex Zisson, Dr. Michael Wasserman, and the Reporting Person are the managing directors of H.I.G. BioVentures - Calhoun, LLC, an affiliate of H.I.G. Capital. The Reporting Person disclaims beneficial ownership of the shares owned by H.I.G. BioVentures - Calhoun, LLC except to the extent of his pecuniary interests therein.

F3 · ownership.nature: All shares of the Series H Preferred Stock, par value $0.001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.001 per share ("Common Stock") immediately prior to the closing of the Issuer's initial public offering of its Common Stock.

SEC source: 0000899243-21-031829 · doc4.xml · derivative · entry 6

Robertson Bruce C · CIK 0001289625 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 13,628

Underlying: Common Stock · 46,875 shares

Expires not disclosed

F2 · derivative.exercise_price: Shares and warrant held by H.I.G. BioVentures - Calhoun, LLC. Affiliates of H.I.G. Capital manage all aspects of H.I.G. BioVentures - Calhoun, LLC. Anthony Tamer and Sami Mnaymneh are the managing partners of H.I.G. Capital and as such have the right to direct all activities related thereto. Alex Zisson, Dr. Michael Wasserman, and the Reporting Person are the managing directors of H.I.G. BioVentures - Calhoun, LLC, an affiliate of H.I.G. Capital. The Reporting Person disclaims beneficial ownership of the shares owned by H.I.G. BioVentures - Calhoun, LLC except to the extent of his pecuniary interests therein.

F4 · kind: The warrant was automatically net exercised for Series H Preferred Stock immediately prior to the closing of the Issuer's initial public offering of its Common Stock.

F2 · price: Shares and warrant held by H.I.G. BioVentures - Calhoun, LLC. Affiliates of H.I.G. Capital manage all aspects of H.I.G. BioVentures - Calhoun, LLC. Anthony Tamer and Sami Mnaymneh are the managing partners of H.I.G. Capital and as such have the right to direct all activities related thereto. Alex Zisson, Dr. Michael Wasserman, and the Reporting Person are the managing directors of H.I.G. BioVentures - Calhoun, LLC, an affiliate of H.I.G. Capital. The Reporting Person disclaims beneficial ownership of the shares owned by H.I.G. BioVentures - Calhoun, LLC except to the extent of his pecuniary interests therein.

F2 · derivative.exercise_date: Shares and warrant held by H.I.G. BioVentures - Calhoun, LLC. Affiliates of H.I.G. Capital manage all aspects of H.I.G. BioVentures - Calhoun, LLC. Anthony Tamer and Sami Mnaymneh are the managing partners of H.I.G. Capital and as such have the right to direct all activities related thereto. Alex Zisson, Dr. Michael Wasserman, and the Reporting Person are the managing directors of H.I.G. BioVentures - Calhoun, LLC, an affiliate of H.I.G. Capital. The Reporting Person disclaims beneficial ownership of the shares owned by H.I.G. BioVentures - Calhoun, LLC except to the extent of his pecuniary interests therein.

F2 · derivative.expiration_date: Shares and warrant held by H.I.G. BioVentures - Calhoun, LLC. Affiliates of H.I.G. Capital manage all aspects of H.I.G. BioVentures - Calhoun, LLC. Anthony Tamer and Sami Mnaymneh are the managing partners of H.I.G. Capital and as such have the right to direct all activities related thereto. Alex Zisson, Dr. Michael Wasserman, and the Reporting Person are the managing directors of H.I.G. BioVentures - Calhoun, LLC, an affiliate of H.I.G. Capital. The Reporting Person disclaims beneficial ownership of the shares owned by H.I.G. BioVentures - Calhoun, LLC except to the extent of his pecuniary interests therein.

F3 · ownership.nature: All shares of the Series H Preferred Stock, par value $0.001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.001 per share ("Common Stock") immediately prior to the closing of the Issuer's initial public offering of its Common Stock.

SEC source: 0000899243-21-031829 · doc4.xml · derivative · entry 5

Robertson Bruce C · CIK 0001289625 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 60,503

Underlying: Common Stock · 60,503 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Shares and warrant held by H.I.G. BioVentures - Calhoun, LLC. Affiliates of H.I.G. Capital manage all aspects of H.I.G. BioVentures - Calhoun, LLC. Anthony Tamer and Sami Mnaymneh are the managing partners of H.I.G. Capital and as such have the right to direct all activities related thereto. Alex Zisson, Dr. Michael Wasserman, and the Reporting Person are the managing directors of H.I.G. BioVentures - Calhoun, LLC, an affiliate of H.I.G. Capital. The Reporting Person disclaims beneficial ownership of the shares owned by H.I.G. BioVentures - Calhoun, LLC except to the extent of his pecuniary interests therein.

F4 · kind: The warrant was automatically net exercised for Series H Preferred Stock immediately prior to the closing of the Issuer's initial public offering of its Common Stock.

F2 · price: Shares and warrant held by H.I.G. BioVentures - Calhoun, LLC. Affiliates of H.I.G. Capital manage all aspects of H.I.G. BioVentures - Calhoun, LLC. Anthony Tamer and Sami Mnaymneh are the managing partners of H.I.G. Capital and as such have the right to direct all activities related thereto. Alex Zisson, Dr. Michael Wasserman, and the Reporting Person are the managing directors of H.I.G. BioVentures - Calhoun, LLC, an affiliate of H.I.G. Capital. The Reporting Person disclaims beneficial ownership of the shares owned by H.I.G. BioVentures - Calhoun, LLC except to the extent of his pecuniary interests therein.

F2 · derivative.exercise_date: Shares and warrant held by H.I.G. BioVentures - Calhoun, LLC. Affiliates of H.I.G. Capital manage all aspects of H.I.G. BioVentures - Calhoun, LLC. Anthony Tamer and Sami Mnaymneh are the managing partners of H.I.G. Capital and as such have the right to direct all activities related thereto. Alex Zisson, Dr. Michael Wasserman, and the Reporting Person are the managing directors of H.I.G. BioVentures - Calhoun, LLC, an affiliate of H.I.G. Capital. The Reporting Person disclaims beneficial ownership of the shares owned by H.I.G. BioVentures - Calhoun, LLC except to the extent of his pecuniary interests therein.

F2 · derivative.expiration_date: Shares and warrant held by H.I.G. BioVentures - Calhoun, LLC. Affiliates of H.I.G. Capital manage all aspects of H.I.G. BioVentures - Calhoun, LLC. Anthony Tamer and Sami Mnaymneh are the managing partners of H.I.G. Capital and as such have the right to direct all activities related thereto. Alex Zisson, Dr. Michael Wasserman, and the Reporting Person are the managing directors of H.I.G. BioVentures - Calhoun, LLC, an affiliate of H.I.G. Capital. The Reporting Person disclaims beneficial ownership of the shares owned by H.I.G. BioVentures - Calhoun, LLC except to the extent of his pecuniary interests therein.

F3 · ownership.nature: All shares of the Series H Preferred Stock, par value $0.001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.001 per share ("Common Stock") immediately prior to the closing of the Issuer's initial public offering of its Common Stock.

SEC source: 0000899243-21-031829 · doc4.xml · derivative · entry 4

Robertson Bruce C · CIK 0001289625 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 0

Underlying: Series H Preferred Stock · 60,503 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · kind: The warrant was automatically net exercised for Series H Preferred Stock immediately prior to the closing of the Issuer's initial public offering of its Common Stock.

F2 · price: Shares and warrant held by H.I.G. BioVentures - Calhoun, LLC. Affiliates of H.I.G. Capital manage all aspects of H.I.G. BioVentures - Calhoun, LLC. Anthony Tamer and Sami Mnaymneh are the managing partners of H.I.G. Capital and as such have the right to direct all activities related thereto. Alex Zisson, Dr. Michael Wasserman, and the Reporting Person are the managing directors of H.I.G. BioVentures - Calhoun, LLC, an affiliate of H.I.G. Capital. The Reporting Person disclaims beneficial ownership of the shares owned by H.I.G. BioVentures - Calhoun, LLC except to the extent of his pecuniary interests therein.

F4 · derivative.expiration_date: The warrant was automatically net exercised for Series H Preferred Stock immediately prior to the closing of the Issuer's initial public offering of its Common Stock.

F3 · ownership.nature: All shares of the Series H Preferred Stock, par value $0.001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.001 per share ("Common Stock") immediately prior to the closing of the Issuer's initial public offering of its Common Stock.

SEC source: 0000899243-21-031829 · doc4.xml · derivative · entry 3

Robertson Bruce C · CIK 0001289625 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 0

Underlying: Common Stock · 403,355 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Shares and warrant held by H.I.G. BioVentures - Calhoun, LLC. Affiliates of H.I.G. Capital manage all aspects of H.I.G. BioVentures - Calhoun, LLC. Anthony Tamer and Sami Mnaymneh are the managing partners of H.I.G. Capital and as such have the right to direct all activities related thereto. Alex Zisson, Dr. Michael Wasserman, and the Reporting Person are the managing directors of H.I.G. BioVentures - Calhoun, LLC, an affiliate of H.I.G. Capital. The Reporting Person disclaims beneficial ownership of the shares owned by H.I.G. BioVentures - Calhoun, LLC except to the extent of his pecuniary interests therein.

F2 · price: Shares and warrant held by H.I.G. BioVentures - Calhoun, LLC. Affiliates of H.I.G. Capital manage all aspects of H.I.G. BioVentures - Calhoun, LLC. Anthony Tamer and Sami Mnaymneh are the managing partners of H.I.G. Capital and as such have the right to direct all activities related thereto. Alex Zisson, Dr. Michael Wasserman, and the Reporting Person are the managing directors of H.I.G. BioVentures - Calhoun, LLC, an affiliate of H.I.G. Capital. The Reporting Person disclaims beneficial ownership of the shares owned by H.I.G. BioVentures - Calhoun, LLC except to the extent of his pecuniary interests therein.

F2 · derivative.exercise_date: Shares and warrant held by H.I.G. BioVentures - Calhoun, LLC. Affiliates of H.I.G. Capital manage all aspects of H.I.G. BioVentures - Calhoun, LLC. Anthony Tamer and Sami Mnaymneh are the managing partners of H.I.G. Capital and as such have the right to direct all activities related thereto. Alex Zisson, Dr. Michael Wasserman, and the Reporting Person are the managing directors of H.I.G. BioVentures - Calhoun, LLC, an affiliate of H.I.G. Capital. The Reporting Person disclaims beneficial ownership of the shares owned by H.I.G. BioVentures - Calhoun, LLC except to the extent of his pecuniary interests therein.

F2 · derivative.expiration_date: Shares and warrant held by H.I.G. BioVentures - Calhoun, LLC. Affiliates of H.I.G. Capital manage all aspects of H.I.G. BioVentures - Calhoun, LLC. Anthony Tamer and Sami Mnaymneh are the managing partners of H.I.G. Capital and as such have the right to direct all activities related thereto. Alex Zisson, Dr. Michael Wasserman, and the Reporting Person are the managing directors of H.I.G. BioVentures - Calhoun, LLC, an affiliate of H.I.G. Capital. The Reporting Person disclaims beneficial ownership of the shares owned by H.I.G. BioVentures - Calhoun, LLC except to the extent of his pecuniary interests therein.

F3 · ownership.nature: All shares of the Series H Preferred Stock, par value $0.001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.001 per share ("Common Stock") immediately prior to the closing of the Issuer's initial public offering of its Common Stock.

SEC source: 0000899243-21-031829 · doc4.xml · derivative · entry 2

Robertson Bruce C · CIK 0001289625 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 0

Underlying: Common Stock · 968,054 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: All shares of the Series G Preferred Stock, par value $0.001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.001 per share ("Common Stock") immediately prior to the closing of the Issuer's initial public offering of its Common Stock.

F1 · price: All shares of the Series G Preferred Stock, par value $0.001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.001 per share ("Common Stock") immediately prior to the closing of the Issuer's initial public offering of its Common Stock.

F1 · derivative.exercise_date: All shares of the Series G Preferred Stock, par value $0.001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.001 per share ("Common Stock") immediately prior to the closing of the Issuer's initial public offering of its Common Stock.

F1 · derivative.expiration_date: All shares of the Series G Preferred Stock, par value $0.001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.001 per share ("Common Stock") immediately prior to the closing of the Issuer's initial public offering of its Common Stock.

F3 · ownership.nature: All shares of the Series H Preferred Stock, par value $0.001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.001 per share ("Common Stock") immediately prior to the closing of the Issuer's initial public offering of its Common Stock.

SEC source: 0000899243-21-031829 · doc4.xml · nonDerivative · entry 1

Robertson Bruce C · CIK 0001289625 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 1,385,037

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: All shares of the Series G Preferred Stock, par value $0.001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.001 per share ("Common Stock") immediately prior to the closing of the Issuer's initial public offering of its Common Stock.

F2 · price: Shares and warrant held by H.I.G. BioVentures - Calhoun, LLC. Affiliates of H.I.G. Capital manage all aspects of H.I.G. BioVentures - Calhoun, LLC. Anthony Tamer and Sami Mnaymneh are the managing partners of H.I.G. Capital and as such have the right to direct all activities related thereto. Alex Zisson, Dr. Michael Wasserman, and the Reporting Person are the managing directors of H.I.G. BioVentures - Calhoun, LLC, an affiliate of H.I.G. Capital. The Reporting Person disclaims beneficial ownership of the shares owned by H.I.G. BioVentures - Calhoun, LLC except to the extent of his pecuniary interests therein.

F3 · ownership.nature: All shares of the Series H Preferred Stock, par value $0.001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.001 per share ("Common Stock") immediately prior to the closing of the Issuer's initial public offering of its Common Stock.

SEC source: 0000899243-21-031826 · doc4.xml · derivative · entry 10

Tammenoms Bakker Juliet · CIK 0001431159 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 0

Underlying: Common Stock · 8,177 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: All shares of the Series H Preferred Stock, par value $0.001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.001 per share ("Common Stock") immediately prior to the closing of the Issuer's initial public offering of its Common Stock.

F2 · price: All shares of the Series H Preferred Stock, par value $0.001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.001 per share ("Common Stock") immediately prior to the closing of the Issuer's initial public offering of its Common Stock.

F2 · derivative.exercise_date: All shares of the Series H Preferred Stock, par value $0.001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.001 per share ("Common Stock") immediately prior to the closing of the Issuer's initial public offering of its Common Stock.

F2 · derivative.expiration_date: All shares of the Series H Preferred Stock, par value $0.001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.001 per share ("Common Stock") immediately prior to the closing of the Issuer's initial public offering of its Common Stock.

F3 · ownership.nature: Shares and warrant are held by Longitude Venture Partners II, L.P. ("LVP II"). Longitude Capital Partners II, LLC ("LCP II") is the general partner of LVP II and may be deemed to have voting and investment power over the securities held by LVP II. The Reporting Person, a member of the Issuer's board of directors, is a managing member of LCP II and may be deemed to share voting and investment power over the securities held by LVP II. LVP II, LCP II and the Reporting Person disclaim beneficial ownership of such shares except to the extent of their respective pecuniary interests therein.

SEC source: 0000899243-21-031826 · doc4.xml · derivative · entry 9

Tammenoms Bakker Juliet · CIK 0001431159 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 8,177

Underlying: Common Stock · 28,125 shares

Expires not disclosed

F2 · derivative.exercise_price: All shares of the Series H Preferred Stock, par value $0.001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.001 per share ("Common Stock") immediately prior to the closing of the Issuer's initial public offering of its Common Stock.

F5 · kind: The warrant was automatically net exercised for Series H Preferred Stock immediately prior to the closing of the Issuer's initial public offering of its Common Stock.

F2 · price: All shares of the Series H Preferred Stock, par value $0.001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.001 per share ("Common Stock") immediately prior to the closing of the Issuer's initial public offering of its Common Stock.

F2 · derivative.exercise_date: All shares of the Series H Preferred Stock, par value $0.001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.001 per share ("Common Stock") immediately prior to the closing of the Issuer's initial public offering of its Common Stock.

F2 · derivative.expiration_date: All shares of the Series H Preferred Stock, par value $0.001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.001 per share ("Common Stock") immediately prior to the closing of the Issuer's initial public offering of its Common Stock.

F3 · ownership.nature: Shares and warrant are held by Longitude Venture Partners II, L.P. ("LVP II"). Longitude Capital Partners II, LLC ("LCP II") is the general partner of LVP II and may be deemed to have voting and investment power over the securities held by LVP II. The Reporting Person, a member of the Issuer's board of directors, is a managing member of LCP II and may be deemed to share voting and investment power over the securities held by LVP II. LVP II, LCP II and the Reporting Person disclaim beneficial ownership of such shares except to the extent of their respective pecuniary interests therein.

SEC source: 0000899243-21-031826 · doc4.xml · derivative · entry 8

Tammenoms Bakker Juliet · CIK 0001431159 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 36,302

Underlying: Common Stock · 36,302 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: All shares of the Series H Preferred Stock, par value $0.001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.001 per share ("Common Stock") immediately prior to the closing of the Issuer's initial public offering of its Common Stock.

F5 · kind: The warrant was automatically net exercised for Series H Preferred Stock immediately prior to the closing of the Issuer's initial public offering of its Common Stock.

F2 · price: All shares of the Series H Preferred Stock, par value $0.001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.001 per share ("Common Stock") immediately prior to the closing of the Issuer's initial public offering of its Common Stock.

F2 · derivative.exercise_date: All shares of the Series H Preferred Stock, par value $0.001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.001 per share ("Common Stock") immediately prior to the closing of the Issuer's initial public offering of its Common Stock.

F2 · derivative.expiration_date: All shares of the Series H Preferred Stock, par value $0.001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.001 per share ("Common Stock") immediately prior to the closing of the Issuer's initial public offering of its Common Stock.

F3 · ownership.nature: Shares and warrant are held by Longitude Venture Partners II, L.P. ("LVP II"). Longitude Capital Partners II, LLC ("LCP II") is the general partner of LVP II and may be deemed to have voting and investment power over the securities held by LVP II. The Reporting Person, a member of the Issuer's board of directors, is a managing member of LCP II and may be deemed to share voting and investment power over the securities held by LVP II. LVP II, LCP II and the Reporting Person disclaim beneficial ownership of such shares except to the extent of their respective pecuniary interests therein.

SEC source: 0000899243-21-031826 · doc4.xml · derivative · entry 7

Tammenoms Bakker Juliet · CIK 0001431159 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 0

Underlying: Series H Preferred Stock · 36,302 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · kind: The warrant was automatically net exercised for Series H Preferred Stock immediately prior to the closing of the Issuer's initial public offering of its Common Stock.

F2 · price: All shares of the Series H Preferred Stock, par value $0.001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.001 per share ("Common Stock") immediately prior to the closing of the Issuer's initial public offering of its Common Stock.

F5 · derivative.expiration_date: The warrant was automatically net exercised for Series H Preferred Stock immediately prior to the closing of the Issuer's initial public offering of its Common Stock.

F3 · ownership.nature: Shares and warrant are held by Longitude Venture Partners II, L.P. ("LVP II"). Longitude Capital Partners II, LLC ("LCP II") is the general partner of LVP II and may be deemed to have voting and investment power over the securities held by LVP II. The Reporting Person, a member of the Issuer's board of directors, is a managing member of LCP II and may be deemed to share voting and investment power over the securities held by LVP II. LVP II, LCP II and the Reporting Person disclaim beneficial ownership of such shares except to the extent of their respective pecuniary interests therein.

SEC source: 0000899243-21-031826 · doc4.xml · derivative · entry 6

Tammenoms Bakker Juliet · CIK 0001431159 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 0

Underlying: Common Stock · 242,013 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: All shares of the Series H Preferred Stock, par value $0.001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.001 per share ("Common Stock") immediately prior to the closing of the Issuer's initial public offering of its Common Stock.

F2 · price: All shares of the Series H Preferred Stock, par value $0.001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.001 per share ("Common Stock") immediately prior to the closing of the Issuer's initial public offering of its Common Stock.

F2 · derivative.exercise_date: All shares of the Series H Preferred Stock, par value $0.001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.001 per share ("Common Stock") immediately prior to the closing of the Issuer's initial public offering of its Common Stock.

F2 · derivative.expiration_date: All shares of the Series H Preferred Stock, par value $0.001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.001 per share ("Common Stock") immediately prior to the closing of the Issuer's initial public offering of its Common Stock.

F3 · ownership.nature: Shares and warrant are held by Longitude Venture Partners II, L.P. ("LVP II"). Longitude Capital Partners II, LLC ("LCP II") is the general partner of LVP II and may be deemed to have voting and investment power over the securities held by LVP II. The Reporting Person, a member of the Issuer's board of directors, is a managing member of LCP II and may be deemed to share voting and investment power over the securities held by LVP II. LVP II, LCP II and the Reporting Person disclaim beneficial ownership of such shares except to the extent of their respective pecuniary interests therein.

SEC source: 0000899243-21-031826 · doc4.xml · derivative · entry 5

Tammenoms Bakker Juliet · CIK 0001431159 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 0

Underlying: Common Stock · 1,613,423 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: All shares of the Series G Preferred Stock, par value $0.001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.001 per share ("Common Stock") immediately prior to the closing of the Issuer's initial public offering of its Common Stock.

F1 · price: All shares of the Series G Preferred Stock, par value $0.001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.001 per share ("Common Stock") immediately prior to the closing of the Issuer's initial public offering of its Common Stock.

F1 · derivative.exercise_date: All shares of the Series G Preferred Stock, par value $0.001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.001 per share ("Common Stock") immediately prior to the closing of the Issuer's initial public offering of its Common Stock.

F1 · derivative.expiration_date: All shares of the Series G Preferred Stock, par value $0.001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.001 per share ("Common Stock") immediately prior to the closing of the Issuer's initial public offering of its Common Stock.

F3 · ownership.nature: Shares and warrant are held by Longitude Venture Partners II, L.P. ("LVP II"). Longitude Capital Partners II, LLC ("LCP II") is the general partner of LVP II and may be deemed to have voting and investment power over the securities held by LVP II. The Reporting Person, a member of the Issuer's board of directors, is a managing member of LCP II and may be deemed to share voting and investment power over the securities held by LVP II. LVP II, LCP II and the Reporting Person disclaim beneficial ownership of such shares except to the extent of their respective pecuniary interests therein.

SEC source: 0000899243-21-031826 · doc4.xml · nonDerivative · entry 4

Tammenoms Bakker Juliet · CIK 0001431159 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 500,000

F4 · ownership.nature: Shares are held by Longitude Prime Fund, L.P. ("LPF"). Longitude Prime Partners, LLC ("LPP") is the general partner of LPF and may be deemed to have voting and investment power over the securities held by LPF. The Reporting Person, a member of the Issuer's board of directors, is a managing member of LPP and may be deemed to share voting and investment power over the securities held by LPF. LPF, LPP and the Reporting Person disclaim beneficial ownership of such shares except to the extent of their respective pecuniary interests therein.

SEC source: 0000899243-21-031826 · doc4.xml · nonDerivative · entry 3

Tammenoms Bakker Juliet · CIK 0001431159 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 1,988,613

F3 · ownership.nature: Shares and warrant are held by Longitude Venture Partners II, L.P. ("LVP II"). Longitude Capital Partners II, LLC ("LCP II") is the general partner of LVP II and may be deemed to have voting and investment power over the securities held by LVP II. The Reporting Person, a member of the Issuer's board of directors, is a managing member of LCP II and may be deemed to share voting and investment power over the securities held by LVP II. LVP II, LCP II and the Reporting Person disclaim beneficial ownership of such shares except to the extent of their respective pecuniary interests therein.

SEC source: 0000899243-21-031826 · doc4.xml · nonDerivative · entry 2

Tammenoms Bakker Juliet · CIK 0001431159 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 1,863,613

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: All shares of the Series G Preferred Stock, par value $0.001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.001 per share ("Common Stock") immediately prior to the closing of the Issuer's initial public offering of its Common Stock.

F2 · price: All shares of the Series H Preferred Stock, par value $0.001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.001 per share ("Common Stock") immediately prior to the closing of the Issuer's initial public offering of its Common Stock.

F3 · ownership.nature: Shares and warrant are held by Longitude Venture Partners II, L.P. ("LVP II"). Longitude Capital Partners II, LLC ("LCP II") is the general partner of LVP II and may be deemed to have voting and investment power over the securities held by LVP II. The Reporting Person, a member of the Issuer's board of directors, is a managing member of LCP II and may be deemed to share voting and investment power over the securities held by LVP II. LVP II, LCP II and the Reporting Person disclaim beneficial ownership of such shares except to the extent of their respective pecuniary interests therein.

SEC source: 0000899243-21-031826 · doc4.xml · nonDerivative · entry 1

Tammenoms Bakker Juliet · CIK 0001431159 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,359

SEC source: 0000899243-21-031823 · doc4.xml · nonDerivative · entry 1

Corley Jesse Anderson · CIK 0001874878 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 436,201

F1 · ownership.nature: Shares held by Andy Corley Living Trust dated 7/17/2013, for which the Reporting Person serves as trustee.

SEC source: 0000899243-21-031822 · doc4.xml · derivative · entry 3

LINK WILLIAM J PHD · CIK 0001228684 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 0

Underlying: Common Stock · 2,016,778 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: All shares of the Series H Preferred Stock, par value $0.001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.001 per share ("Common Stock") immediately prior to the closing of the Issuer's initial public offering of its Common Stock.

F1 · price: All shares of the Series H Preferred Stock, par value $0.001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.001 per share ("Common Stock") immediately prior to the closing of the Issuer's initial public offering of its Common Stock.

F1 · derivative.exercise_date: All shares of the Series H Preferred Stock, par value $0.001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.001 per share ("Common Stock") immediately prior to the closing of the Issuer's initial public offering of its Common Stock.

F1 · derivative.expiration_date: All shares of the Series H Preferred Stock, par value $0.001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.001 per share ("Common Stock") immediately prior to the closing of the Issuer's initial public offering of its Common Stock.

F2 · ownership.nature: Shares held by RxSight I, LLC. The Reporting Person is a managing member of RxSight I, LLC and may be deemed to share voting and investment power over the securities held by RxSight I, LLC. The Reporting Person disclaims beneficial ownership of such shares except to the extent of his respective pecuniary interests therein.

SEC source: 0000899243-21-031822 · doc4.xml · nonDerivative · entry 2

LINK WILLIAM J PHD · CIK 0001228684 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 37,109

SEC source: 0000899243-21-031822 · doc4.xml · nonDerivative · entry 1

LINK WILLIAM J PHD · CIK 0001228684 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 2,016,778

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: All shares of the Series H Preferred Stock, par value $0.001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.001 per share ("Common Stock") immediately prior to the closing of the Issuer's initial public offering of its Common Stock.

F2 · ownership.nature: Shares held by RxSight I, LLC. The Reporting Person is a managing member of RxSight I, LLC and may be deemed to share voting and investment power over the securities held by RxSight I, LLC. The Reporting Person disclaims beneficial ownership of such shares except to the extent of his respective pecuniary interests therein.

SEC source: 0000899243-21-031821 · doc4.xml · nonDerivative · entry 1

Weinberg Eric · CIK 0001295814 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 31,250

SEC source: 0000899243-21-031814 · doc4.xml · nonDerivative · entry 1

Kurtz Ronald M MD · CIK 0001295469 · Director · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 125,000

SEC source: 0000899243-21-031812 · doc4.xml · nonDerivative · entry 3

Andrews Julie · CIK 0001550508 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 29,003

SEC source: 0000899243-21-031812 · doc4.xml · nonDerivative · entry 2

Andrews Julie · CIK 0001550508 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,378

F1 · security: Each restricted stock unit ("RSU") represents a contingent right to receive one share of RxSight, Inc. Common Stock.

F3 · shares: Subject to the Reporting Person's continuing as an Outside Director (as defined in the Issuer's 2021 Equity Incentive Plan) through such applicable vesting date, one third of the RSUs subject to the award shall vest on each annual anniversary of August 3, 2021.

F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of RxSight, Inc. Common Stock.

SEC source: 0000899243-21-031812 · doc4.xml · nonDerivative · entry 1

Andrews Julie · CIK 0001550508 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,733

F1 · security: Each restricted stock unit ("RSU") represents a contingent right to receive one share of RxSight, Inc. Common Stock.

F2 · shares: Subject to the Reporting Person's continuing as an Outside Director (as defined in the Issuer's 2021 Equity Incentive Plan) through such applicable vesting date, one hundred percent (100%) of the RSUs subject to the award shall vest on the date immediately prior to the first annual meeting of stockholders following August 3, 2021.

F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of RxSight, Inc. Common Stock.

SEC source: 0000899243-21-031811 · doc4.xml · nonDerivative · entry 2

PALMISANO ROBERT J · CIK 0001138646 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,378

F1 · security: Each restricted stock unit ("RSU") represents a contingent right to receive one share of RxSight, Inc. Common Stock.

F3 · shares: Subject to the Reporting Person's continuing as an Outside Director (as defined in the Issuer's 2021 Equity Incentive Plan) through such applicable vesting date, one third of the RSUs subject to the award shall vest on each annual anniversary of August 3, 2021.

F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of RxSight, Inc. Common Stock.

SEC source: 0000899243-21-031811 · doc4.xml · nonDerivative · entry 1

PALMISANO ROBERT J · CIK 0001138646 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,733

F1 · security: Each restricted stock unit ("RSU") represents a contingent right to receive one share of RxSight, Inc. Common Stock.

F2 · shares: Subject to the Reporting Person's continuing as an Outside Director (as defined in the Issuer's 2021 Equity Incentive Plan) through such applicable vesting date, one hundred percent (100%) of the RSUs subject to the award shall vest on the date immediately prior to the first annual meeting of stockholders following August 3, 2021.

F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of RxSight, Inc. Common Stock.

SEC source: 0000899243-21-031808 · doc4.xml · nonDerivative · entry 3

Warner Robert Keith · CIK 0001874373 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 57,128

F4 · ownership.nature: Shares held by the Cabo Living Trust, for which the Reporting Person serves as trustee.

SEC source: 0000899243-21-031808 · doc4.xml · nonDerivative · entry 2

Warner Robert Keith · CIK 0001874373 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,378

F1 · security: Each restricted stock unit ("RSU") represents a contingent right to receive one share of RxSight, Inc. Common Stock.

F3 · shares: Subject to the Reporting Person's continuing as an Outside Director (as defined in the Issuer's 2021 Equity Incentive Plan) through such applicable vesting date, one third of the RSUs subject to the award shall vest on each annual anniversary of August 3, 2021.

F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of RxSight, Inc. Common Stock.

SEC source: 0000899243-21-031808 · doc4.xml · nonDerivative · entry 1

Warner Robert Keith · CIK 0001874373 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,733

F1 · security: Each restricted stock unit ("RSU") represents a contingent right to receive one share of RxSight, Inc. Common Stock.

F2 · shares: Subject to the Reporting Person's continuing as an Outside Director (as defined in the Issuer's 2021 Equity Incentive Plan) through such applicable vesting date, one hundred percent (100%) of the RSUs subject to the award shall vest on the date immediately prior to the first annual meeting of stockholders following August 3, 2021.

F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of RxSight, Inc. Common Stock.

SEC source: 0000899243-21-031996 · doc4.xml · nonDerivative · entry 3

Weinberg Eric · CIK 0001295814 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · By fiance

Disclosed balance after: 301

SEC source: 0000899243-21-031996 · doc4.xml · nonDerivative · entry 2

Weinberg Eric · CIK 0001295814 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · By fiance

Disclosed balance after: 300

F2 · price: Represents the weighted average share price of an aggregate total of 90 shares purchased in the price range of $16.45 to $17.05 by the Reporting Person's fiance. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.

SEC source: 0000899243-21-031121 · doc4.xml · derivative · entry 1

Weinberg Eric · CIK 0001295814 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 87,437

Underlying: Common Stock · 87,437 shares

Expires 2031-07-31

F1 · derivative.exercise_date: Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable date, one forty-eighth (1/48th) of the shares subject to the option shall vest each month following the Vesting Commencement Date on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). "Vesting Commencement Date" shall mean July 30, 2021.

SEC source: 0000899243-21-031116 · doc4.xml · derivative · entry 1

Kurtz Ronald M MD · CIK 0001295469 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 338,819

Underlying: Common Stock · 338,819 shares

Expires 2031-07-31

F1 · derivative.exercise_date: Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable date, one forty-eighth (1/48th) of the shares subject to the option shall vest each month following the Vesting Commencement Date on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). "Vesting Commencement Date" shall mean July 30, 2021.

SEC source: 0000899243-21-031114 · doc4.xml · derivative · entry 1

Thunen Shelley B · CIK 0001297491 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 98,367

Underlying: Common Stock · 98,367 shares

Expires 2031-07-31

F1 · derivative.exercise_date: Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable date, one forty-eighth (1/48th) of the shares subject to the option shall vest each month following the Vesting Commencement Date on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). "Vesting Commencement Date" shall mean July 30, 2021.

SEC source: 0000899243-21-031113 · doc4.xml · derivative · entry 1

Goldshleger Ilya · CIK 0001874147 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 98,367

Underlying: Common Stock · 98,367 shares

Expires 2031-07-31

F1 · derivative.exercise_date: Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable date, one forty-eighth (1/48th) of the shares subject to the option shall vest each month following the Vesting Commencement Date on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). "Vesting Commencement Date" shall mean July 30, 2021.

SEC source: 0000899243-21-031109 · doc4.xml · nonDerivative · entry 1

Tammenoms Bakker Juliet · CIK 0001431159 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,859

F1 · security: Each restricted stock unit ("RSU") represents a contingent right to receive one share of RxSight, Inc. Common Stock

F2 · shares: Subject to the Reporting Person's continuing as an Outside Director (as defined in the Issuer's 2021 Equity Incentive Plan) through such applicable vesting date, one hundred percent (100%) of the RSUs subject to the award shall vest on the date immediately prior to the first annual meeting of stockholders following July 30, 2021.

F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of RxSight, Inc. Common Stock

SEC source: 0000899243-21-031106 · doc4.xml · nonDerivative · entry 1

LINK WILLIAM J PHD · CIK 0001228684 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,859

F1 · security: Each restricted stock unit ("RSU") represents a contingent right to receive one share of RxSight, Inc. Common Stock

F2 · shares: Subject to the Reporting Person's continuing as an Outside Director (as defined in the Issuer's 2021 Equity Incentive Plan) through such applicable vesting date, one hundred percent (100%) of the RSUs subject to the award shall vest on the date immediately prior to the first annual meeting of stockholders following July 30, 2021.

F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of RxSight, Inc. Common Stock

SEC source: 0000899243-21-031098 · doc4.xml · nonDerivative · entry 1

Corley Jesse Anderson · CIK 0001874878 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,859

F1 · security: Each restricted stock unit ("RSU") represents a contingent right to receive one share of RxSight, Inc. Common Stock.

F2 · shares: Subject to the Reporting Person's continuing as an Outside Director (as defined in the Issuer's 2021 Equity Incentive Plan) through such applicable vesting date, one hundred percent (100%) of the RSUs subject to the award shall vest on the date immediately prior to the first annual meeting of stockholders following July 30, 2021.

F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of RxSight, Inc. Common Stock.

SEC source: 0000899243-21-031996 · doc4.xml · nonDerivative · entry 1

Weinberg Eric · CIK 0001295814 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · By fiance

Disclosed balance after: 210

F1 · price: Represents the weighted average share price of an aggregate total of 210 shares purchased in the price range of $16.90 to $16.94 by the Reporting Person's fiance. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.